Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jun 23;11(6):e043083.
doi: 10.1136/bmjopen-2020-043083.

Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study

Affiliations
Multicenter Study

Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study

Xiaomei Xu et al. BMJ Open. .

Abstract

Objectives: We aimed to evaluate recompensation factors among patients with decompensated cirrhosis.

Design: A multicentre retrospective case-control study was conducted. Data were collected from and compared between groups of patients with recompensated and acute decompensated cirrhosis. Univariable and multivariable logistic regressions were used to select indicators associated with recompensation among patients with decompensated cirrhosis with different complications. A decision tree with 10-fold cross-validation was used to develop the model to identify patients with recompensation. We followed the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guideline for development and reporting of the new model.

Setting: The study was conducted in six tertiary public hospitals in Chongqing, China.

Participants: This study included 3953 patients with decompensated cirrhosis.

Results: In the total sample of included patients, there were 553 patients with recompensation and 3400 patients with acute decompensation, including 1158 patients with gastrointestinal bleeding, 1715 patients with a bacterial infection, 104 patients with hepatic encephalopathy and 423 patients with ascites. The most relevant indicator of recompensation selected by the decision tree model was albumin, with a threshold of 40 g/L. Total protein, haemoglobin, basophil percentage, alanine aminotransferase, neutrophil-to-lymphocyte ratio and diabetes were also selected to subsequently distinguish patients. The terminal nodes with a probability of recompensation was 0.89. The overall accuracy rate of the model was 0.92 (0.91-0.93), and it exhibited high specificity (86.9%) and sensitivity (92.6%).

Conclusions: The occurrence of recompensated cirrhosis could be identified by albumin, total protein, haemoglobin, basophil percentage, alanine aminotransferase, neutrophil-to-lymphocyte ratio and diabetes. These simple variables may help clinicians develop a treatment plan to encourage patients with decompensated cirrhosis to recompensate.

Keywords: hepatobiliary disease; hepatology; risk management.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Decision tree plot for identifying recompensated cirrhosis. Each node shows the percentage of patients classified and their probability of recompensation (also represented by the colours and colour intensity). The blue colour represents acute decompensated cirrhosis. The green colour represents recompensated cirrhosis. The intensity of the colour indicates the accuracy of the classification of each category, the more intense the colour, the higher the accuracy.

References

    1. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver . EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69:406–60. 10.1016/j.jhep.2018.03.024 - DOI - PubMed
    1. Moreau R, Jalan R, Gines P, et al. . Acute-On-Chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426–37. 10.1053/j.gastro.2013.02.042 - DOI - PubMed
    1. Chinese Society of Hepatology, Chinese Medical Association . [Chinese guidelines on the management of liver cirrhosis]. Zhonghua Gan Zang Bing Za Zhi 2019;27:846–65. 10.3760/cma.j.issn.1007-3418.2019.11.008 - DOI - PubMed
    1. Zhao H, Wang Q, Luo C, et al. . Recompensation of decompensated hepatitis B cirrhosis: current status and challenges. Biomed Res Int 2020;2020:1–7. 10.1155/2020/9609731 - DOI - PMC - PubMed
    1. Shim JH, Lee HC, Kim KM, et al. . Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176–82. 10.1016/j.jhep.2009.11.007 - DOI - PubMed

Publication types